Financial Times Recognizes Cravath in its 2019 North America Innovative Lawyers Report
December 11, 2019
On December 10, 2019, Cravath was recognized by the Financial Times in its annual “North America Innovative Lawyers” report. The Firm was ranked in the “Litigation and Disputes” and “Managing Complexity and Scale” categories for Innovation in Legal Expertise, and Cravath partner Mark I. Greene was named one of the year’s “Top 10 Legal Innovators.”
In the “Litigation and Disputes” category, the Firm was “highly commended” for its representation of Qualcomm in achieving a multibillion‑dollar global settlement and six‑year licensing agreement with Apple. In the “Managing Complexity and Scale” category, Cravath was “commended” for its work navigating multiple jurisdictions to structure Mylan’s pending combination with Upjohn.
Related Practices & Industries
People
- Photo
-
-
J.D., 1993, University of Pennsylvania Law School
-
B.A., 1989, Cornell University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
May 08, 2019
Qualcomm and Apple Settle Worldwide Litigation and Enter into License Agreement and Chipset Supply Agreement
On April 16, 2019, Cravath client Qualcomm announced an agreement with Apple to dismiss all litigation between the two companies worldwide, with a settlement that includes a payment from Apple to Qualcomm. The companies also reached a global six‑year license agreement, effective as of April 1, 2019, including a two‑year option to extend, and a multiyear chipset supply agreement.
Deals & Cases
July 29, 2019
Mylan’s $50 Billion Combination with Upjohn, a Division of Pfizer
On July 29, 2019, Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan shareholders would own 43%. Cravath is representing Mylan in connection with the transaction.
